Tofacitnib Citrate

ʻO ka wehewehe pōkole:

Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP
Tofacitnib Citrate Rheumatoid arthritis I-Hale      


Huahana Huahana

Huahana Huahana

NUI HUA

Ka hope

ʻO Tofacitinib citrate, ka mea i ʻike ʻia ʻo CP-690550 citrate, he mea paʻa ikaika o janus kinase 3 (JAK3), he tyrosine kinase hematopoetic cell-restricted tyrosine kinase i komo i ka transduction hōʻailona e hoʻoponopono ana i ke ola lymphocyte, proliferation, differentiation, a me apoptosis.ʻO ka inhibition ʻo JAK3 kikoʻī me kahi koho 1000-fold ma mua o nā kinases ʻohana non-JAK.Ma waho aʻe o ka pale ʻana i ka JAKS (IC50 = 1 nM), ʻo tofacitinib citrate ka mea e pale ai i ka janus kinase 2 (JAK2) a me ka janus kinase 1 (JAK1) me ka 20- a me 100-fold ka liʻiliʻi o ka potency.Eia naʻe, i loko o kahi noiʻi hou, ua hōʻike ʻia nā pili pili (Ki) o tofacitinib citrate e pili ana iā JAK1, JAK2, a me JAK3 he 1.6 nM, 21.7 nM, a me 6.5 nM.

Kuhikuhi

Lalitha Vijayakrishnan, R. Venkataramanan a me Palak Gulati.Ka mālama ʻana i ka mumū me ka janus kinase inhibitor CP-690,550.Nā Kūlana i loko o Pharmacological Sciences 2011: 32 (1);25-34

Huahana Huahana

  • 1. Panagi I, Jennings E, et al."Hoʻololi ʻo Salmonella Effector SteE i ka Mammalian Serine/Threonine Kinase GSK3 i loko o kahi Tyrosine Kinase e kuhikuhi i ka Polarization Macrophage."Pūnaewele Host Microbe.2020;27(1):41–53.e6.PMID:31862381
  • 2. McInnes IB, Byers NL, et al."ʻO ka hoʻohālikelike o ka baricitinib, upadacitinib, a me tofacitinib i hoʻoponopono i ka hoʻoponopono o ka cytokine hōʻailona i nā subpopulations leukocyte kanaka."ʻO ka Arthritis Res Ther.2019 ʻAukake 2;21(1):183.PMID:31375130
  • 3. Liu S, Verma M, et al."Ke kū'ē steroid o ke ea type 2 innate lymphoid cell mai nā poʻe maʻi me ka hānō koʻikoʻi: ʻO ke kuleana o thymic stromal lymphopoietin." J Allergy Clin Immunol.2018 Ian;141(1):257-268.e6.PMID:28433687
  • 4. Zheng, Lufeng, et al."ʻO ka 3' UTR o ka pseudogene CYP4Z2P e hoʻoikaika i ka angiogenesis tumor i ka maʻi kanesa o ka umauma ma o ka hana ʻana he ceRNA no CYP4Z1."Ka noiʻi a me ka mālama ʻana i ka maʻi maʻi umauma (2015): 1-14.PMID:25701119

wehewehe

ʻO Tofacitinib citrate kahi mea hoʻopaneʻe JAK1 / 2/3 waha me IC50s o 1, 20, a me 112 nM.Loaʻa i ka Tofacitinib citrate nā hana antibacterial, antifungal a me antiviral.

Waihona

4°C, pale mai ka malamalama

*Ma ka solvent: -80°C, 6 mahina;-20°C, 1 mahina (pale mai ka malamalama)

 

ʻO ke kinona

Tofacitnib Citrate

ʻIkepili olaola pili

Tofacitnib Citrate2

ʻIkepili olaola pili

Tofacitnib Citrate3

ʻIkepili olaola pili

Tofacitnib Citrate4

ʻIkepili olaola pili

Tofacitnib Citrate5

ʻIkepili olaola pili

Tofacitnib Citrate6

HOOLAHA ANOAI

Quality management1

Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6nā papahana ma lalo o ka ʻae ʻia.

Quality management2

Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.

Quality management3

Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.

Quality management4

Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kau inoa ʻana.

HOOLAHA HANA

cpf5
cpf6

Kolea Countec Bottled Packaging Line

cpf7
cpf8

ʻO Taiwan CVC Bottled Packaging Line

cpf9
cpf10

ʻO Italia CAM Board Packaging Line

cpf11

Mekini Fette Compacting German

cpf12

ʻO Iapana Viswill Tablet ʻIke

cpf14-1

Keena Mana DCS

HOA

Ka launa pū ʻana o ka honua
International cooperation
ʻO ka launa pū ʻana o ka hale
Domestic cooperation

  • Mua:
  • Aʻe:

  • E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou